TJ Talks cover art

TJ Talks

TJ Talks

Written by: Tumori Journal
Listen for free

About this listen

TJ Talks is an educational initiative featuring conversations about oncology led by Prof. Giancarlo Pruneri, Editor in Chief of Tumori Journal.

The podcast series aims to explore a variety of topics of interest that reflect the dynamic and evolving nature of oncology research, with contributions from renowned international experts and promising young researchers in the field. Through these insightful discussions, TJ Talks seeks to support the professional development of clinicians and researchers working to improve the cancer care.

TJ Talks will be available from September on our website and on the best podcast platforms.

Follow us on Twitter and LinkedIn to always be updated on cancer research and clinical practice in oncology!

Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Primary and Surrogate Endpoints in Clinical Trials: Implementation and Challenges in Daily Practice
    Nov 26 2025

    The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.

    In this TJ Talks dedicated to the hot topic of endpoints in clinical trials, Gabriele Zoppoli, Associate Professor of Medicine at University of Genoa and Internal Medicine Consultant at Policlinico San Martino (Genoa) meet Erman Akkus, MD at Ankara University, Faculty of Medicine, Department of Medical Oncology.

    Alongside “primary clinical endpoints”, which concern overall survival and quality of life, surrogate endpoints are early or indirect measures of these primary endpoints, such as progression-free survival and response rate. Their purpose? To facilitate clinical trials and drug approval, but surrogate endpoints are still an active area of research and are the subject of debate in oncology. Meanwhile, patients' perceptions are waiting to be taken more seriously.

    Get insights, listen to the TJ Talks podcast

    See omnystudio.com/listener for privacy information.

    Show More Show Less
    13 mins
  • Pharmaco-prevention in Breast Cancer: a strategy to halve the incidence of a potentially fatal disease
    Oct 23 2025

    Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection.

    In this TJ Talks podcast, together with Prof. Andrea De Censi, director of the Breast Unit at the Champalimaud Foundation in Lisbon, Portugal, here in conversation with Prof. Antonino Musolino (director of the Medical Oncology Unit at the IRCCS-Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Forlì-Cesena), we will examine what practical solutions can bridge the gap between pharmacological prevention, indication and adoption, with a look at the future perspectives in this setting.

    Enjoy your listening!

    See omnystudio.com/listener for privacy information.

    Show More Show Less
    14 mins
  • The last journey: the invisible needs of migrant patients between palliative care and the need for protection
    Sep 25 2025

    Stories of foreign cancer patients who ask to return to their country at the end of their lives: their deep desire to see their loved ones one last time is intertwined with medical, legal and financial issues that seem insurmountable. In this TJ Talks, Dr Sergio Defendi, director of Palliative Care and Home Care at Asst Crema, who has been providing assistance with end-of-life travel for years, discusses this issue together with Dr Luca Zambelli, from the Palliative Care Unit of the IRCCS National Cancer Institute Foundation in Milan.

    How should the responsibility for end-of-life repatriation be managed? Clinical uncertainty, the legal issue of the use of certain drugs, and the protection of patients and accompanying doctors should be addressed in guidelines or care pathways that deal with this sensitive issue. This is the next challenge for the oncology community.

    Enjoy your listening!

    See omnystudio.com/listener for privacy information.

    Show More Show Less
    17 mins
No reviews yet